Search Results 191-200 of 17430 for Interferon

1. A Study of the Effectiveness and Safety of Lanreotide Autogel/ Depot for Patients who have Lung Neuroendocrine Tumors - Mayo Clinic

   ... interferon for Lung NET. Participating Mayo Clinic locations. Study statuses change often. Please contact the study team for the most up-to-date information ...

2. Amlodipine and atorvastatin (oral route) - Side effects & dosage - Mayo Clinic

   Interferon Beta; Kratom; Norethindrone; Oat Bran; Pectin; Pioglitazone; Quinine; Rifampin; Rifapentine; St John's Wort; Ticagrelor; Warfarin. Other Interactions.

3. Multiple Sclerosis Clinical Trials - Mayo Clinic Research

   To examine the safety and efficacy of initial alemtuzumab treatment in this study for patients who received Rebif® (interferon beta-1a) as their study treatment ...

4. A Study of Avatrombopag for the Treatment of Thrombocytopenia in Patients with Chronic Liver Disease Undergoing an Elective Procedure - Mayo Clinic

   Interferon (IFN) use within 14 days of screening; Estrogen-containing hormonal contraceptive or hormone replacement therapy use within 30 days of screening ...

5. Drugs and Supplements that Start with B - Mayo Clinic

   Interferon beta-1b (subcutaneous route). Betatar Gel. Also known as. Coal tar (topical route) · Betaxolol (ophthalmic route) · Betaxolol (oral route).

6. Efficacy and Safety of Benralizumab in EGPA Compared to Mepolizumab - Mayo Clinic

   ... interferon-? or alemtuzumab within 6 months prior to screening, receipt of anti-tumor necrosis factor therapy within 12 weeks prior to screening or an ...

7. A Phase 2/3 Study To Investigate The Safety And Efficacy Of Brepocitinib In Adults With Lichen Planopilaris (ALPINE) - Mayo Clinic

   A positive interferon gamma release assay (IGRA), noting the following: If the results of the IGRA are indeterminate, the test may be repeated once, and if ...

8. A Randomized Phase 2 Trial of Axitinib and TRC105 Versus Axitinib Alone in Patients With Advanced or Metastatic Renal Cell Carcinoma - Mayo Clinic

   One prior immunotherapy (interleukin-2 or interferon-alpha or immune checkpoint inhibitor or tumor vaccine) and one prior mTOR inhibitor treatment are allowed.

9. A Study Evaluating the Safety and Efficacy of KITE-585 in Subjects With Relapsed/Refractory Multiple Myeloma - Mayo Clinic

   ... interferon-γ (61.45 pg/mL) and interleukin-2 (0.9 pg/mL). KITE-585 demonstrated a manageable safety profile; however, the limited CAR T-cell expansion and ...

10. A Study to Compare the Effectiveness and Safety of JCAR017 to Standard of Care in Adult Subjects With High-risk, Transplant-eligible Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphomas - Mayo Clinic

    Systemic immunostimulatory agents (including but not limited to interferon and IL-2) within 6 weeks or 5 half-lives of the drug, whichever is shorter, prior to ...